{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=GCSF&page=11", "query": { "intervention": "GCSF", "page": 11 }, "page_size": 10 }, "pagination": { "page": 11, "page_size": 10, "total_count": 1135, "total_pages": 114, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=GCSF&page=12&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=GCSF&page=10&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-17T07:32:11.484Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06001788", "title": "Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "AML", "AML With Mutated NPM1", "Hematologic Malignancy", "KMT2Ar", "NPM1 Mutation", "MLL Rearrangement", "Leukemia", "Acute Myeloid Leukemia", "Leukemia, Myeloid", "Leukemia, Myeloid, Acute", "Acute Leukemia", "Neoplasms by Histologic Type" ], "interventions": [ { "name": "Ziftomenib", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Idarubicin", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Gilteritinib", "type": "DRUG" }, { "name": "Granulocyte colony-stimulating factor", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Kura Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 171, "start_date": "2024-02-22", "completion_date": "2027-08", "has_results": false, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-10-17T07:32:11.484Z", "location_count": 38, "location_summary": "Gilbert, Arizona • Los Angeles, California • Orange, California + 32 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06001788" }, { "nct_id": "NCT05115630", "title": "Off-the-shelf NK Cells + SCT for Myeloid Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myeloid Malignancies", "Acute Myeloid Leukemia", "Myelodysplastic Syndrome", "Chronic Myeloid Leukemia" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Filgrastim", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Fludarabine phosphate", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Mycophenolate mofetil", "type": "DRUG" }, { "name": "Total Body Irradiation One Dose", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 24, "start_date": "2022-04-08", "completion_date": "2025-05-15", "has_results": true, "last_update_posted_date": "2025-12-19", "last_synced_at": "2026-10-17T07:32:11.484Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05115630" }, { "nct_id": "NCT04959175", "title": "Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hematologic Neoplasms" ], "interventions": [ { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Allogeneic HSCT", "type": "PROCEDURE" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Filgrastim", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Total Body Irradiation (TBI)", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "12 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "12 Years to 85 Years" }, "enrollment_count": 320, "start_date": "2021-09-23", "completion_date": "2027-04-30", "has_results": false, "last_update_posted_date": "2026-10-16", "last_synced_at": "2026-10-17T07:32:11.484Z", "location_count": 2, "location_summary": "Bethesda, Maryland • Philadelphia, Pennsylvania", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04959175" }, { "nct_id": "NCT03579875", "title": "Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Fanconi Anemia", "Severe Aplastic Anemia", "Myelodysplastic Syndromes", "T Cell Receptor Alpha/Beta Depletion", "Telomere Biology Disorder", "Bone Marrow Failure", "Dyskeratosis Congenita", "Telomere Biology Disorders" ], "interventions": [ { "name": "Total Body Irradiation (TBI) (Plan 1)", "type": "DRUG" }, { "name": "Cyclophosphamide (CY) (Plan 1)", "type": "DRUG" }, { "name": "Fludarabine (FLU)", "type": "DRUG" }, { "name": "Methylprednisolone (MP)", "type": "DRUG" }, { "name": "Donor mobilized PBSC infusion", "type": "DEVICE" }, { "name": "G-CSF", "type": "DRUG" }, { "name": "Cyclophosphamide (CY) (Plan 2)", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Alemtuzumab", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "65 Years", "sex": "ALL", "summary": "Up to 65 Years" }, "enrollment_count": 48, "start_date": "2018-11-13", "completion_date": "2029-01-05", "has_results": false, "last_update_posted_date": "2026-01-30", "last_synced_at": "2026-10-17T07:32:11.484Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03579875" }, { "nct_id": "NCT07278856", "title": "Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Follicular Helper T-Cell Lymphoma", "Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type", "Follicular Helper T-Cell Lymphoma, Follicular-Type", "Follicular Helper T-Cell Lymphoma, Not Otherwise Specified", "Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma", "Peripheral T-Cell Lymphoma, Not Otherwise Specified" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "FDG-Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Filgrastim", "type": "BIOLOGICAL" }, { "name": "Fludeoxyglucose F-18", "type": "OTHER" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Pegfilgrastim", "type": "BIOLOGICAL" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Ruxolitinib Phosphate", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2025-12-16", "completion_date": "2027-03-31", "has_results": false, "last_update_posted_date": "2026-06-05", "last_synced_at": "2026-10-17T07:32:11.484Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07278856" }, { "nct_id": "NCT00651937", "title": "Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma", "Primary Amyloidosis" ], "interventions": [ { "name": "Melphalan", "type": "DRUG" }, { "name": "Stem Cell Infusion", "type": "PROCEDURE" }, { "name": "Questionnaires", "type": "BEHAVIORAL" }, { "name": "Granulocyte-colony stimulating factor (G-CSF)", "type": "DRUG" }, { "name": "Apheresis", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE", "BEHAVIORAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 80, "start_date": "2008-03", "completion_date": "2016-01", "has_results": true, "last_update_posted_date": "2020-01-14", "last_synced_at": "2026-10-17T07:32:11.484Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00651937" }, { "nct_id": "NCT04370795", "title": "Matched Related and Unrelated Donor Stem Cell Transplantation for Severe Combined Immune Deficiency (SCID): Busulfan-based Conditioning With h-ATG, Radiation, and Sirolimus", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Severe Combined Immune Deficiency (SCID)" ], "interventions": [ { "name": "Sirolimus", "type": "DRUG" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Horse -Anti-thymocyte", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" }, { "name": "Total Body Irradiation (TBI)", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "3 Years to 40 Years" }, "enrollment_count": 0, "start_date": "2025-11-26", "completion_date": "2025-11-26", "has_results": false, "last_update_posted_date": "2025-12-01", "last_synced_at": "2026-10-17T07:32:11.484Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04370795" }, { "nct_id": "NCT00002601", "title": "Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Sarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sarcoma" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "ifosfamide", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "10 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "10 Years to 55 Years" }, "enrollment_count": 13, "start_date": "1994-09", "completion_date": "2014-09", "has_results": true, "last_update_posted_date": "2017-03-03", "last_synced_at": "2026-10-17T07:32:11.484Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002601" }, { "nct_id": "NCT00002675", "title": "Chemotherapy in Treating Patients With Retinoblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Retinoblastoma" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "mesna", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "17 Years", "sex": "ALL", "summary": "Up to 17 Years" }, "enrollment_count": 50, "start_date": "1995-05", "completion_date": "2001-01", "has_results": false, "last_update_posted_date": "2013-06-28", "last_synced_at": "2026-10-17T07:32:11.484Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002675" }, { "nct_id": "NCT03147612", "title": "Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Acute Lymphoblastic Leukemia", "Acute Myeloid Leukemia With BCR-ABL1", "Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Recurrent Acute Lymphoblastic Leukemia", "Refractory Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Blinatumomab", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Filgrastim", "type": "BIOLOGICAL" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Pegfilgrastim", "type": "BIOLOGICAL" }, { "name": "Ponatinib", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Vincristine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2018-02-08", "completion_date": "2027-02-28", "has_results": false, "last_update_posted_date": "2026-08-19", "last_synced_at": "2026-10-17T07:32:11.484Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03147612" } ] }